| 31.22 1.28 (4.28%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.19 | 1-year : | 45.37 |
| Resists | First : | 34.41 | Second : | 38.84 |
| Pivot price | 35.36 |
|||
| Supports | First : | 27.23 | Second : | 22.66 |
| MAs | MA(5) : | 33.88 |
MA(20) : | 34.29  |
| MA(100) : | 30.99 |
MA(250) : | 25.1 |
|
| MACD | MACD : | 0.4 |
Signal : | 1 |
| %K %D | K(14,3) : | 29.2 |
D(3) : | 48.5 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 39.52 | Low : | 14.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TECX ] has closed above bottom band by 2.7%. Bollinger Bands are 49.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 32.01 - 32.18 | 32.18 - 32.35 |
| Low: | 28.52 - 28.74 | 28.74 - 28.94 |
| Close: | 30.88 - 31.22 | 31.22 - 31.53 |
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Wed, 02 Sep 2026
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case - Seeking Alpha
Tue, 01 Sep 2026
Tectonic Therapeutic Loses US$152m Market Value But Insiders See Windfall Of US$72k - simplywall.st
Thu, 27 Aug 2026
Tectonic (NASDAQ: TECX) ex-director lines up another stock sale - Stock Titan
Fri, 21 Aug 2026
Tectonic Therapeutic (NASDAQ: TECX) ex-director to sell 10,200 shares - Stock Titan
Thu, 06 Aug 2026
Tectonic Therapeutic, Inc. Stock 12‑Month Price Target Cut to $77.56, Implies 157% Upside - TradingView
Mon, 27 Jul 2026
TECX|Tectonic Therapeutic Inc|Price:35.620|Chg%:-1.080 - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 37.8 (%) |
| Held by Institutions | 71.6 (%) |
| Shares Short | 1,760 (K) |
| Shares Short P.Month | 2,140 (K) |
| EPS | -4.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -33.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -6.84 |
| PEG Ratio | 0 |
| Price to Book value | 2.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|